Eli Lilly (LLY)
$911.38
13.28 (1.48%)
LLY Stock Quote Delayed 30 Minutes
3 Reasons to Stop Worrying and Invest Now
It may seem crazy to buy stocks right now, but hoarding cash isn't any safer. The real worry is what could happen if you are not invested in the market.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
1.12M
Day's Range
$896.90 - $914.77
52-Week Range
$434.34 - $918.50
Dividend & Yield
$4.52 (0.50%)
LLY Stock Predictions, Articles, and Eli Lilly News
Johnson & Johnson a Safe Play for Income
JNJ's financials are solid, and the company is making strides toward getting 11 new drugs approved by the end of 2015.
Big Pharma Banking on New Cancer Treatment Approach to Boost Sales
GlaxoSmithKline, Eli Lilly and Novartis are among the companies studying epigenetics -- a new approach to fighting cancer that is already seeing some success.
Kraft Spins Off Snacks, Wisely Bucking 2011 Buyout Boom
While the buyout frenzy still has legs, some companies, like Kraft, appear to be bucking the trend. Here's why it's not a bad move.
Is Pfizer Move to Sell Non-Pharma Divisions Bad Medicine?
Pfizer has said it will shed its nutritional and animal health businesses to pump more money into its drug pipeline. But is the move risky?
Lilly Study Could Sink Prospects for Alzheimer’s Treatments
Eli Lilly's drug study failure raises questions about the safety of its Alzheimer's treatment, but will rival Bristol-Myers have success?
Conoco Phillips Gushes As Real America Index Moves Higher
Arkansas' Conoco Phillips NYSE:COP jumped 2.2% today, one of the biggest moves in the Real America Index. Lilly NYSE:LLY and Sprint NYSE:S also had big stock moves.
Alkermes Looks to Enter Biotech Big Leagues
CEO orchestrates a transformation that could leave the company poised for further growth.
ObamaCare Court Test a Non-event for Health Stocks
Health insurance, pharmaceutical companies' gains show confidence that ObamaCare is all but a done deal.
Big Pharma Stocks Have Big Challenges Ahead
Tougher FDA approvals and expiring patents mean good times for Big Pharma could be fleeting, but a few stocks are worth striking at while the iron's hot.
Health Care ETFs May Be Your Best Big Pharma Play
Health care stocks and ETFs are a part of most portfolios, but drug companies have fallen on hard times.
